How Neuropeptides Control Joint Pain and Drive Osteoarthritis Progression | Research

The takeaway

Four key neuropeptides — substance P, CGRP, VIP, and neuropeptide Y — play central roles in both generating and reducing joint pain, and their interplay with the central nervous system suggests future therapies could target these peptides to treat osteoarthritis.

4 key neuropeptides
Substance P, CGRP, VIP, and neuropeptide Y are the major peptides controlling both pain generation and pain reduction in joints, working locally and in the CNS simultaneously

What the researchers found

The review identifies substance P, calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP), and neuropeptide Y as the four major neuropeptides involved in joint pain — both in generating pain signals after trauma and in modulating pain reduction. Critically, the neuropeptide changes observed in subchondral bone and synovial tissue are mirrored in the central nervous system, indicating a bidirectional communication system.

These neuropeptides interact with each other and with cytokines in a complex cascade that determines how pain signals are generated, transmitted, and perceived. The joint functions as an integrated organ where local neuropeptide signaling and CNS processing work together to respond to mechanical load, injury, and inflammation.

Why it matters

Osteoarthritis affects hundreds of millions of people worldwide and current pain treatments are limited. Understanding that neuropeptides are not just pain messengers but active regulators of joint health and disease opens entirely new therapeutic avenues. Rather than simply blocking pain signals, future treatments could target the specific neuropeptide pathways driving both pain and joint degeneration.

How the study worked

Systematic literature review covering papers published between January 1990 and September 2017, searched across Web of Science Core Collection, MEDLINE, and Scopus databases. The review synthesizes findings on neuropeptide roles in joint pain transmission and osteoarthritis progression.

What this study cannot tell us

As a narrative literature review, this paper synthesizes existing evidence without performing a meta-analysis or reporting pooled quantitative results. The proposed slow-release antibody cocktail treatment remains theoretical with no clinical data. The literature search ended in 2017, so more recent findings may not be included. The review focuses on osteoarthritis and may not fully address other joint conditions.

How to read the evidence

This is a narrative literature review synthesizing nearly three decades of research on neuropeptides in joint biology. While it provides a comprehensive overview, it does not include systematic search methodology details, quality assessment of included studies, or quantitative synthesis. It ranks as a useful overview but below systematic reviews in evidence strength.

When this study was published

Published in 2019 with literature coverage through 2017. The core neuropeptide biology remains relevant, though newer research on anti-CGRP therapies and neuropeptide-targeted biologics may have advanced the therapeutic concepts discussed.

The bigger picture

This review reframes the joint as a neuro-regulated organ rather than a purely mechanical structure. It connects to the growing field of neuroimmunology, where the nervous system's peptide signals are recognized as key drivers of inflammatory disease. The proposed concept of slow-release neuropeptide-targeting cocktails aligns with broader trends in precision medicine and biologics development for chronic inflammatory conditions.

Questions still open

Could antibody cocktails targeting multiple neuropeptides simultaneously provide better joint pain relief than targeting a single pathway?
How do the neuropeptide changes in joints relate to central sensitization and chronic pain states in osteoarthritis patients?
What role do these neuropeptides play in cartilage regeneration versus degeneration?

Common questions

What are neuropeptides and how do they affect joint pain?

Neuropeptides are small protein-like molecules released by nerve cells that carry signals between neurons and other cells. In joints, neuropeptides like substance P and CGRP transmit pain signals from injured tissue to the brain, while others like VIP and neuropeptide Y can help modulate or reduce pain. They also influence inflammation and tissue repair, making them key players in conditions like osteoarthritis.

Could targeting neuropeptides treat osteoarthritis?

The review suggests this is a promising future direction. The authors propose that a slow-release combination of antibodies blocking pain-promoting neuropeptides and drugs activating pain-reducing neuropeptide receptors could address early joint pain and inflammation. While this concept has not yet been tested clinically for joints, similar approaches — like anti-CGRP antibodies for migraine — are already in use for other pain conditions.

Read the original research

Neuropeptides: important regulators of joint homeostasis.

Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 27(3), 942-949

View on PubMed ↗Publisher’s paper ↗

Citation

Gatenholm, Birgitta; Brittberg, Mats. (2019). Neuropeptides: important regulators of joint homeostasis.. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 27(3), 942-949. https://doi.org/10.1007/s00167-018-5074-4